John Karanicolas
Overview
Explore the profile of John Karanicolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
3947
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrianov G, Haroldsen E, Karanicolas J
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596415
The enthusiastic adoption of make-on-demand chemical libraries for virtual screening has highlighted the need for methods that deliver improved hit-finding discovery rates. Traditional virtual screening methods are often inaccurate, with...
2.
Bychkov I, Deneka A, Topchu I, Pangeni R, Ismail A, Lengner C, et al.
Res Sq
. 2024 Apr;
PMID: 38659828
Lung cancer is one of the most common types of cancer worldwide. Non-small cell lung cancer (NSCLC), typically caused by and driver mutations, represents the majority of all new lung...
3.
Mischley V, Maier J, Chen J, Karanicolas J
bioRxiv
. 2024 Apr;
PMID: 38559274
Protein-protein interactions underlie nearly all cellular processes. With the advent of protein structure prediction methods such as AlphaFold2 (AF2), models of specific protein pairs can be built extremely accurately in...
4.
Widstrom N, Andrianov G, Heier J, Heier C, Karanicolas J, Parker L
ACS Chem Biol
. 2023 Dec;
19(1):117-128.
PMID: 38159292
The TAM family of receptor tyrosine kinases is implicated in multiple distinct oncogenic signaling pathways. However, to date, there are no FDA-approved small molecule inhibitors for the TAM kinases. Inhibitor...
5.
Quinn C, Rico M, Merali C, Barrero C, Perez-Leal O, Mischley V, et al.
Sci Transl Med
. 2023 Sep;
15(715):eade2966.
PMID: 37756380
Hepatic fibrosis is the primary determinant of mortality in patients with metabolic dysfunction-associated steatohepatitis (MASH). Transforming growth factor-β (TGFβ), a master profibrogenic cytokine, is a promising therapeutic target that has...
6.
Ong W, Kirubakaran P, Karanicolas J
bioRxiv
. 2023 Sep;
PMID: 37732243
The extreme surge of interest over the past decade surrounding the use of neural networks has inspired many groups to deploy them for predicting binding affinities of drug-like molecules to...
7.
Bychkov I, Deneka A, Topchu I, Pangeni R, Lengner C, Karanicolas J, et al.
bioRxiv
. 2023 Jul;
PMID: 37398283
Significance: This study shows the novel role of Musashi-2 as regulator of ATM expression and DDR in lung cancer.
8.
Indeglia A, Leung J, Miller S, Leu J, Dougherty J, Clarke N, et al.
Cancer Discov
. 2023 May;
13(7):1696-1719.
PMID: 37140445
Significance: We analyze the African-centric Y107H hypomorphic variant and show that it confers increased cancer risk; we use Y107H in order to identify PADI4 as a key tumor-suppressive p53 target...
9.
Bai N, Adeshina Y, Bychkov I, Xia Y, Gowthaman R, Miller S, et al.
Res Sq
. 2023 Jan;
PMID: 36711552
RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a "hotspot pharmacophore" from the...
10.
Bai N, Adeshina Y, Bychkov I, Xia Y, Gowthaman R, Miller S, et al.
bioRxiv
. 2023 Jan;
PMID: 36711508
RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a "hotspot pharmacophore" from the...